You searched for novodiag - Page 6 of 6

Mobidiag Signs Agreement with Bioportugal Química Farmacêutica Lda for the Distribution of Amplidiag® Diagnostics Tests in Portugal

ESPOO, Finland, September 26^th, 2016 – Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Bioportugal Química Farmacêutica Lda, expert provider of products for the life science market (diagnostics, pharmaceutical, hospital furniture and equipment), for the distribution of the Amplidiag^® product line. Under this agreement Bioportugal becomes the exclusive distributor of Amplidiag^®, in vitro diagnostics for gastrointestinal infections, in Portugal.

“For the past months, we have been extending significantly our European distribution network. With a strong background in diagnostics, Bioportugal seemed to be the clear choice to distribute our IVD tests in Portugal. We are then very pleased to expand even more Amplidiag accessibility with the support of Bioportugal” said Tuomas Tenkanen, CEO at Mobidiag.

Mobidiag Extends Agreement with Biomedica Medizinprodukte GmbH & Co KG for Distribution of Amplidiag® Diagnostics Tests in Central and Eastern Europe (CEE)

ESPOO, Finland, September 5^th, 2016 – Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Biomedica Medizinprodukte GmbH & Co KG, provider of a large panel of medical products for health professionals, medical scientists, and research laboratories, for the distribution of the Amplidiag^® product line. Under this new agreement Biomedica Medizinprodukte becomes the exclusive distributor of Amplidiag^®, in vitro diagnostics for gastrointestinal infections, in Central and Eastern Europe (Austria, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia).

Mobidiag Announces Release of Amplidiag® Stool Parasites (CE-IVD), a Multiplex PCR Test to Detect Parasites Directly from Stool Samples

Mobidiag Announces Release of Amplidiag^® Stool Parasites (CE-IVD), a Multiplex PCR Test to Detect Parasites Directly from Stool Samples

ESPOO, Finland, August 29^th, 2016 – Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the launch of its CE-IVD marked Amplidiag^® Stool Parasites kit, a molecular test allowing detection of the main diarrhea causing stool parasites: Giardia lamblia, Cryptosporidium spp., Entamoeba histolytica and Dientamoeba fragilis.

Pathogenic protozoa are the main causative agents of parasite-associated gastroenteritis due to their ability to multiply in humans. If not detected and treated in time, they can cause diarrhea and a wide variety of other prolonged symptoms, such as colitis, abdominal discomfort, and nausea, symptoms that compromise quality of human life. As a result, infections caused by stool parasites raise important public health challenges with a strong economic impact globally.

Mobidiag invited by MTV3 to present its diagnostics solutions

Mobidiag’s CEO Tuomas Tenkanen was invited this morning to major Finnish television channel MTV3, along with expert Jaana Vuopio (Professor, University of Turku), to talk about the global threat of resistant super bacteria. These bacteria are very difficult to detect and treat, and can often lead to serious infections. For the past years, new technologies have been introduced to diagnose these bacteria as early as possible but they were shown to be either too expensive or unadapted to routine diagnostics.

Press Release: Mobidiag Presents Two New Diagnostic Platforms at ECCMID 2015

Novodiag™ and Amplidiag™ Easy platforms to serve both low- and high-throughput customer needs with emphasis on accessibility and affordability

Espoo, Finland – April 22, 2015 – Mobidiag Ltd, a Finnish molecular diagnostics company specializing in the development of innovative diagnostics solutions for infectious diseases, today announced the first public presentation of two new diagnostic platforms – Novodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.

The entirely new Novodiag platform is a fully integrated and automated system, enabling accessible and affordable molecular testing. The platform enables fast, very easy to use and highly multiplexed on-demand molecular testing for any throughput needs. It combines advanced features, ease of use, and affordability unmatched by currently available products, and requires no dedicated molecular testing expertise. The Novodiag platform will be readied for a full commercial launch in mid-2016 to serve various testing needs in the infectious diseases space, as well as in other potential markets which are unserved by current molecular platforms.